On the 20th, it was reported that the latest research results of Chinese medical experts have improved the clinical benefits of first-line treatment for non-small cell lung cancer, bringing a new and better choice of immune combined anti vascular synergistic anti-tumor therapy for patients with advanced squamous non-small cell lung cancer (referred to as lung squamous cell carcinoma). Professor Lu Shun, the leader of oncology at Shanghai Chest Hospital and director of Shanghai Pulmonary Tumor Clinical Medicine Center, led a research exploration on the efficacy and safety of the world's first "tumor immunity+anti angiogenesis" bispecific antibody - Ivoxidan anti combination chemotherapy first-line treatment for advanced squamous non-small cell lung cancer, opening up a new paradigm for the treatment of advanced lung squamous cell carcinoma. The relevant treatment mode has successfully filled the key gap in the treatment of lung squamous cell carcinoma with anti angiogenic drugs, achieving an important upgrade in this field. It is reported that Yiwo Xidan Kang is a PD-1/VEGF bispecific tumor immunotherapy drug independently developed by China. Compared to traditional immune drugs, it has both anti-tumor therapeutic effects and can avoid the bleeding problem of anti angiogenic drugs. On October 19th Beijing time, the relevant results were published in the renowned international academic journal The Lancet. On the same day, the study was also presented as the latest breakthrough abstract (LBA) at the 2025 European Society of Oncology (ESMO2025) conference. It is reported that lung squamous cell carcinoma accounts for 35% of the total incidence of non-small cell lung cancer, and about 70% of lung squamous cell carcinoma patients are diagnosed at an advanced stage. Traditional chemotherapy has limited efficacy, with a 5-year survival rate of less than 10% and an overall poor prognosis. With the development of immunotherapy, PD-1 monoclonal antibody combined with chemotherapy has become a widely recognized first-line treatment standard. However, this treatment model also faces many unresolved clinical challenges, such as patient survival bottlenecks and the inability to use anti angiogenic drugs due to bleeding risks. Therefore, there is an urgent need for more breakthrough first-line treatment strategies in clinical practice to achieve dual optimization of efficacy and safety. In related studies, Professor Lu Shun's team randomly assigned patients to receive either Ivoxidan anti combination chemotherapy or Trelizumab combination chemotherapy. The relevant research results show that the median progression free survival of the Ivoxidan antibody group is 11.14 months, while the group treated with Trastuzumab is only 6.9 months. In terms of safety, the Ivoxidan anti group has made a breakthrough in changing the "dilemma" of high bleeding rates in the treatment of lung squamous cell carcinoma with previous anti angiogenic drugs. The research results confirm that the Ivosi therapy has achieved the best progression free survival in the history of first-line treatment for squamous non-small cell lung cancer, greatly prolonging the survival time of such patients and achieving a dual improvement in efficacy and safety. Professor Lu Shun stated that this research not only takes a big step forward in the treatment of non-small cell lung cancer, but also represents a significant breakthrough in the global field of tumor immunotherapy, with the potential to reshape the global cancer treatment landscape. (New Society)